Arrowhead Pharmaceuticals (ARWR) Income from Continuing Operations (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Income from Continuing Operations came in at 137572000.0 in Q1 2026, down 137.4% YoY from 367863000.0 in Q1 2025, and down 587.12% on a QoQ basis from 28242000.0 in Q4 2025.
Powered by 
Analysis
Arrowhead Pharmaceuticals (ARWR) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Income from Continuing Operations data on file, last reported at 137572000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 137.4% year-over-year to 137572000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 271898000.0 (down 75.8% YoY) and the FY2025 annual result came in at 30114000.0, up 104.94% from the prior year.
- Income from Continuing Operations slipped to 137572000.0 in Q1 2026, from 28242000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 367863000.0 in Q1 2025 to a low of 178689000.0 in Q2 2025.
- A 5-year average of 59518411.76 and a median of 104125000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 366.37% — and 2025, when it jumped 389.67%.
- Tracing ARWR's Income from Continuing Operations over 5 years: stood at 41794000.0 in 2022, then plunged by 223.91% to 135376000.0 in 2023, then decreased by 29.43% to 175218000.0 in 2024, then jumped by 116.12% to 28242000.0 in 2025, then slumped by 587.12% to 137572000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 137572000.0 (Q1 2026), 28242000.0 (Q4 2025), and 16121000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.40 Bn | 10.80 Bn | - | -178.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -178.92 Mn |
| Mar 31, 2026 | -137.57 Mn |
| Dec 31, 2025 | 28.24 Mn |
| Sep 30, 2025 | 16.12 Mn |
| Jun 30, 2025 | -178.65 Mn |
| Mar 31, 2025 | 367.86 Mn |
| Dec 31, 2024 | -175.22 Mn |
| Sep 30, 2024 | -173.34 Mn |
| Jun 30, 2024 | -173.98 Mn |
| Mar 31, 2024 | -127.00 Mn |
| Dec 31, 2023 | -135.38 Mn |
| Sep 30, 2023 | -111.02 Mn |
| Jun 30, 2023 | -104.13 Mn |
| Mar 31, 2023 | 47.68 Mn |
| Dec 31, 2022 | -41.81 Mn |
| Sep 30, 2022 | -85.94 Mn |
| Jun 30, 2022 | -72.05 Mn |
| Mar 31, 2022 | 44.37 Mn |
| Dec 31, 2021 | -62.87 Mn |
| Sep 30, 2021 | -63.37 Mn |